Contents

Search

Haemophilus b Conjugate - Meningococcal Protein Conjugate Vaccine (Pedvax HIB, Menhibrix)

Indications: - routine vaccination against invasive disease caused by Haemophilus influenzae type b in infants & children 2-71 months of age - high risk* infants (MenHibrix) [3,4] - complement component deficiency - functional or anatomical asplenia [4] - Menhibrix is FDA-approved to prevent infection by Neisseria meningitidis serogroups C & Y & Haemophilus influenzae type b [2] Dosage: - IM only - 1st dose 2-14 months - booster at 15 months or older (regardless of number of doses given < 15 months) - Menhibrix is a 4 dose series given at 2, 4, 6 & 12-15 months of age Mechanism of action: - Pedvax HIB is a highly purified capsular polysaccharide (polyribosylribitol phosphate or PRP) of Haemophilus influenzae type b (Haemophilus b, Ross strain) that is covalently bound to an outer membrane protein complex (OMPC) of the B11 strain of Neisseria meningitidis serogroup B

General

vaccine combination

References

  1. RxList http://www.rxlist.com/pedvaxhib-drug.htm
  2. FDA News, June 14, 2012 FDA approves new combination vaccine that protects children against two bacterial diseases http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm308350.htm
  3. Reuters, Oct 24, 2012 CDC panel OKs Glaxo's meningitis vaccine for at-risk infants http://news.yahoo.com/cdc-panel-oks-glaxos-meningitis-vaccine-risk-infants-194542818--finance.html
  4. Centers for Disease Control and Prevention Infant Meningococcal Vaccination: Advisory Committee on Immunization Practices (ACIP) Recommendations and Rationale. MMWR. January 25, 2013 / 62(03);52-54 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6203a3.htm

Component-of

haemophilus b conjugate meningococcal protein conjugate vaccine/hepatitis b vaccine hepatitis b vaccine/haemophilus b conjugate vaccine meningococcal protein conjugate